Moberg Pharma AB (publ) (MOB.ST)
SEK 11.28
(10.37%)
SEK 11.28
(10.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.09 Million SEK | -34.26% |
| 2022 | -15.71 Million SEK | 3.16% |
| 2021 | -16.22 Million SEK | 14.74% |
| 2020 | -19.02 Million SEK | 0.0% |
| 2018 | 19.83 Million SEK | 77.79% |
| 2017 | 11.15 Million SEK | -65.84% |
| 2016 | 32.66 Million SEK | 27.92% |
| 2015 | 25.53 Million SEK | 108.16% |
| 2014 | 12.26 Million SEK | 208.01% |
| 2013 | -11.35 Million SEK | -131.71% |
| 2012 | 35.81 Million SEK | 660.98% |
| 2011 | -6.38 Million SEK | 79.43% |
| 2010 | -31.03 Million SEK | -28.04% |
| 2009 | -24.23 Million SEK | 31.43% |
| 2008 | -35.34 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.04 Million SEK | 37.73% |
| 2024 Q1 | -6.49 Million SEK | -0.81% |
| 2023 Q3 | -5.76 Million SEK | -49.69% |
| 2023 Q1 | -5.03 Million SEK | -61.58% |
| 2023 FY | -21.09 Million SEK | -34.26% |
| 2023 Q2 | -3.85 Million SEK | 23.42% |
| 2023 Q4 | -6.44 Million SEK | -11.78% |
| 2022 Q2 | -3.9 Million SEK | 12.09% |
| 2022 Q1 | -4.44 Million SEK | -10.0% |
| 2022 FY | -15.71 Million SEK | 3.16% |
| 2022 Q3 | -4.25 Million SEK | -8.83% |
| 2022 Q4 | -3.11 Million SEK | 26.75% |
| 2021 FY | -16.22 Million SEK | 14.74% |
| 2021 Q4 | -4.03 Million SEK | -3.27% |
| 2021 Q1 | 18.63 Million SEK | 384.09% |
| 2021 Q2 | -3.32 Million SEK | -117.83% |
| 2021 Q3 | -3.91 Million SEK | -17.63% |
| 2020 FY | -19.02 Million SEK | 0.0% |
| 2020 Q1 | -3.4 Million SEK | 14.97% |
| 2020 Q4 | -6.56 Million SEK | -40.61% |
| 2020 Q2 | -5.23 Million SEK | -53.78% |
| 2020 Q3 | -4.66 Million SEK | 10.84% |
| 2019 Q4 | -4 Million SEK | -112.25% |
| 2019 Q1 | 563.9 Million SEK | 5045.12% |
| 2019 Q3 | 32.66 Million SEK | 741.84% |
| 2019 Q2 | -5.08 Million SEK | -100.9% |
| 2018 Q2 | 4.69 Million SEK | 133.78% |
| 2018 FY | 19.83 Million SEK | 77.79% |
| 2018 Q4 | 10.96 Million SEK | 402.98% |
| 2018 Q3 | 2.17 Million SEK | -53.56% |
| 2018 Q1 | 2 Million SEK | -79.02% |
| 2017 Q3 | 12.36 Million SEK | 259.2% |
| 2017 FY | 11.15 Million SEK | -65.84% |
| 2017 Q1 | -3 Million SEK | -21.23% |
| 2017 Q4 | 9.56 Million SEK | -22.61% |
| 2017 Q2 | -7.76 Million SEK | -158.46% |
| 2016 FY | 32.66 Million SEK | 27.92% |
| 2016 Q1 | -5.64 Million SEK | -1540.82% |
| 2016 Q2 | 27.99 Million SEK | 595.66% |
| 2016 Q3 | 12.79 Million SEK | -54.28% |
| 2016 Q4 | -2.47 Million SEK | -119.36% |
| 2015 FY | 25.53 Million SEK | 108.16% |
| 2015 Q1 | 10.91 Million SEK | 4232.95% |
| 2015 Q3 | 8.77 Million SEK | 60.84% |
| 2015 Q2 | 5.45 Million SEK | -49.99% |
| 2015 Q4 | 392 Thousand SEK | -95.53% |
| 2014 Q4 | -264 Thousand SEK | -106.01% |
| 2014 Q2 | 4.06 Million SEK | -0.02% |
| 2014 Q1 | 4.07 Million SEK | 1055.4% |
| 2014 FY | 12.26 Million SEK | 208.01% |
| 2014 Q3 | 4.39 Million SEK | 7.96% |
| 2013 FY | -11.35 Million SEK | -131.71% |
| 2013 Q4 | -426 Thousand SEK | 89.15% |
| 2013 Q3 | -3.92 Million SEK | 7.76% |
| 2013 Q2 | -4.25 Million SEK | -54.67% |
| 2013 Q1 | -2.75 Million SEK | 56.43% |
| 2012 Q2 | 1.36 Million SEK | -96.42% |
| 2012 Q1 | 37.99 Million SEK | 761.17% |
| 2012 FY | 35.81 Million SEK | 660.98% |
| 2012 Q4 | -6.31 Million SEK | -327.78% |
| 2012 Q3 | 2.77 Million SEK | 103.82% |
| 2011 Q2 | -9.55 Million SEK | -43.68% |
| 2011 Q4 | 4.41 Million SEK | -18.52% |
| 2011 Q3 | 5.41 Million SEK | 156.65% |
| 2011 Q1 | -6.65 Million SEK | 25.69% |
| 2011 FY | -6.38 Million SEK | 79.43% |
| 2010 Q1 | -4.68 Million SEK | 0.0% |
| 2010 FY | -31.03 Million SEK | -28.04% |
| 2010 Q3 | -9.38 Million SEK | -17.13% |
| 2010 Q4 | -8.95 Million SEK | 4.62% |
| 2010 Q2 | -8.01 Million SEK | -71.2% |
| 2009 FY | -24.23 Million SEK | 31.43% |
| 2008 FY | -35.34 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -54.065% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 43.248% |
| BioGaia AB (publ) | 365.35 Million SEK | 105.773% |
| Enzymatica AB (publ) | -49.72 Million SEK | 57.583% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 52.72% |
| Gabather AB (publ) | -9.43 Million SEK | -123.514% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 41.055% |
| Nanexa AB (publ) | -76.39 Million SEK | 72.391% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | -36.923% |
| ODI Pharma AB | 355.97 Thousand SEK | 6025.483% |
| Orexo AB (publ) | -128.3 Million SEK | 83.56% |
| Probi AB (publ) | 16.81 Million SEK | 225.412% |
| Swedencare AB (publ) | 58.6 Million SEK | 135.995% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 100.876% |
| Toleranzia AB | -7.45 Million SEK | -182.786% |
| Vivesto AB | -367.03 Million SEK | 94.253% |